Gregory W. Randolph, MD, FACS, FACE, Professor of Otolaryngology–Head and Neck Surgery at Harvard Medical School (HMS) and director of the Thyroid and Parathyroid Endocrine Surgical Division at Mass Eye and Ear, was recently elected president of the International Thyroid Oncology Group (ITOG).
The ITOG is a renowned group of medical oncologists, endocrinologists, surgeons and basic science researchers spanning the globe who are focused on catalyzing a cure for the most challenging and advanced thyroid cancers. Together, they design and conduct clinical trials for new cancer therapies. Dr. Randolph is the first surgeon and otolaryngologist to lead the society.
Dr. Randolph will serve a three-year term as president. During his term, he says he will lead efforts to further promote neoadjuvant clinical trials, which he believes is the next frontier of treating late-stage thyroid cancers.
“I’m incredibly proud to take on this leadership role of an elite group of world-renowned scientists,” said Dr. Randolph, who also serves as the Claire and John Bertucci Endowed Chair in Thyroid Surgical Oncology at HMS. “This is a fantastic opportunity to strengthen ties between medical oncology, endocrinology and surgery to promote optimal thyroid care and further deliver advanced thyroid cancer care at Mass Eye and Ear.”